PIK3CA and breast cancer: Indeed, the FDA recently approved BYL719 (alphelisib) for treating PIK3CA-mutated breast cancer patients in combination with the estrogen receptor degrader, fulvestrant, following a randomized phase 3 clinical trial that showed that a combination of the two agents resulted in improvement in patient outcomes [31].